Generate Biomedicines: The Dosing Interval Is The Moat, Not The Algorithm (NASDAQ:GENB)
· seekingalpha.com
GENB’s golukibart aims for twice-yearly asthma dosing as Phase 3 TSLP trials challenge Tezspire.
Generate Biomedicines ( GENB ) entered the public markets this year as an AI-driven biotech company. I believe the market is evaluating the wrong aspect of the ...